The Effects and Regulatory Mechanism of Targeting CXC Chemokine Receptor 1/2 Combined with Ara-C on the Malignant Biological Behaviors of U937 Cells of Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2023.02.009
- Author:
Yan-Quan LIU
1
;
Jian-Zhen SHEN
2
;
Yue YIN
2
;
Yu-Ting CHEN
1
;
Hui YANG
1
;
Huan-Wen TANG
3
Author Information
1. Department of Hematology, The First Clinical Medical College of Guangdong Medical University, Dongguan Key Laboratory of Environmental Medicine, Dongguan 523808, Guangdong Province, China.
2. Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.
3. Department of Hematology, The First Clinical Medical College of Guangdong Medical University, Dongguan Key Laboratory of Environmental Medicine, Dongguan 523808, Guangdong Province, China,E-mail: thw@gdmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
CXC chemokine receptor;
acute myeloid leukemia;
malignant biological behavior;
regulatory mechanism
- MeSH:
Humans;
U937 Cells;
Cytarabine/therapeutic use*;
Receptors, Interleukin-8A;
NF-kappa B;
Proto-Oncogene Proteins c-akt;
Phosphatidylinositol 3-Kinases;
Leukemia, Myeloid, Acute/genetics*;
Apoptosis;
Cell Proliferation;
Apoptosis Regulatory Proteins;
Proto-Oncogene Proteins c-bcl-2;
RNA, Messenger;
Cell Line, Tumor
- From:
Journal of Experimental Hematology
2023;31(2):364-376
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate and analyze the effect of CXC chemokine receptor 1/2 (CXCR1/2) targeting inhibitor Reparixin combined with cytarabine (Ara-C) on the malignant biological behaviors of acute myeloid leukemia cells and its effect on the expression of the CXCR family, while exploring the accompanying molecular mechanism, providing scientific basis and reference for new molecular markers and targeted therapy for AML.
METHODS:Acute myeloid leukemia U937 cells were treated with different concentrations of Reparixin, Ara-C alone or in combination, and the cell morphology was observed under an inverted microscope; Wright-Giemsa staining was used to detect cell morphological changes; CCK-8 method was used to detect cell proliferation; the ability of cell invasion was detected by Transwell chamber method; the ability of colony formation was detected by colony formation assay; cell apoptosis was detected by Hoechst 33258 fluorescent staining and Annexin V/PI double-staining flow cytometry; monodansylcadaverine(MDC) staining was used to detect cell autophagy; the expression of apoptosis, autophagy and related signaling pathway proteins was detected by Western blot and the expression changes of CXCR family were detected by real-time quantitative polymerase chain reaction (qRT-PCR).
RESULTS:Reparixin could inhibit the proliferation, invasion, migration and clone formation ability of U937 cells. Compared with the single drug group, when U937 cells were intervened by Reparixin combined with Ara-C, the malignant biological behaviors such as proliferation, invasion and colony formation were significantly decreased, and the levels of apoptosis and autophagy were significantly increased (P<0.01). After Reparixin combined with Ara-C intervenes in U937 cells, it can up-regulate the expression of the pro-apoptotic protein Bax and significantly down-regulate the expression of the anti-apoptotic protein Bcl-2, and also hydrolyze and activate Caspase-3, thereby inducing cell apoptosis. Reparixin combined with Ara-C could up-regulate the expressions of LC3Ⅱ and Beclin-1 proteins in U937 cells, and the ratio of LC3Ⅱ/LC3Ⅰ in cells was significantly up-regulated compared with single drug or control group (P<0.01). MDC result showed that the green granules of vesicles increased significantly, and a large number of broken cells were seen (P<0.01). Reparixin combined with Ara-C can significantly inhibit the phosphorylation level of PI3K, AKT and NF-κB signaling molecule, inhibit the malignant biological behavior of cells by inhibiting the activation of PI3K/AKT/NF-κB pathway, and induce programmed cell death. Ara-C intervention in U937 cells had no effect on the expression of CXCR family (P>0.05). The expression of CXCR1, CXCR2, and CXCR4 mRNA could be down-regulated by Reparixin single-agent intervention in U937 cells (P<0.05), and the expression of CXCR2 was more significantly down-regulated than the control group and other CXCRs (P<0.01). When Reparixin and Ara-C intervened in combination, the down-regulated levels of CXCR1 and CXCR2 were more significant than those in the single-drug group (P<0.01), while the relative expressions of CXCR4 and CXCR7 mRNA had no significant difference compared with the single-drug group (P>0.05).
CONCLUSION:Reparixin combined with Ara-C can synergistically inhibit the malignant biological behaviors of U937 cells such as proliferation, invasion, migration and clone formation, and induce autophagy and apoptosis. The mechanism may be related to affecting the proteins expression of Bcl-2 family and down-regulating the proteins expression of CXCR family, while inhibiting the PI3K/AKT/NF-κB signaling pathway.
